Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy

Author(s): Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA


Background— Doxorubicin causes a chronic cardiomyopathy of unknown pathogenesis. We investigated whether acquired defects in mitochondrial DNA (mtDNA) and interconnected respiratory chain dysfunction may represent a molecular mechanism for its late onset.

Methods and Results— Rats were treated weekly with intravenous doxorubicin (1 mg/kg) for 7 weeks, starting at 11 weeks of age (group B). Controls received saline. Group C received doxorubicin identically to group B, but the course was started at 41 weeks of age. All rats were killed at week 48. Doxorubicin was also injected once, either 6 days (group D) or 2 hours (group E) before euthanasia. Heart and skeletal muscle were examined. Only group B rats developed a significant clinical, macroscopic, histological, and ultrastructural cardiomyopathy. Group B hearts had the lowest cytochrome c oxidase (COX) activity (24% of controls; P=0.003), the highest citrate synthase activity (135% of controls; P=0.005), and the highest production of superoxide. In group B, the respiratory subunit COXI, which is encoded by mtDNA, was reduced (P<0.001), as was mtDNA (49% of controls, P<0.001). Group C hearts differed from group B in their lower cardiomyopathy score (P=0.006), higher COX activity (P=0.02), and higher mtDNA content (P=0.04). Group B and to a lesser extent group C hearts contained deleted mtDNA. There was no detectable mitochondrial toxicity in group D and E hearts or in skeletal muscle.

Similar Articles

Cardiotoxicity and cardioprotection in childhood cancer

Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.

Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death

Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience

Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.

Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer

Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.

Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging

Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE

Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child

Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.

Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy

Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure

Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management

Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.